Targeted Cancer Immune Therapy
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , , |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2009.
|
| Edición: | 1st ed. 2009. |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1007/978-1-4419-0170-5 |
Tabla de Contenidos:
- Cytokine Immune Therapy
- Role of IL12 Family in Regulation of Antitumor Immune Response
- IL-18 in Regulation of Antitumor Immune Response and Clinical Application
- Interleukin-21 and Cancer Therapy
- IL-24 in Regulation of Antitumor Immune Response and in Signaling
- IL-28 and IL-29 in Regulation of Antitumor Immune Response and Induction of Tumor Regression
- Passive and Active Tumor Homing Cytokine Therapy
- Cell-based Immune Therapy
- New Strategies to Improve Tumor Cell Vaccine Therapy
- Modification of Dendritic Cells to Enhance Cancer Vaccine Potency
- Dendritic Cell Vaccines for Immunotherapy of Cancer: Challenges in Clinical Trials
- A "Toll Bridge" for Tumor-Specific T Cells
- Engineering Adult Stem Cells for Cancer Immunotherapy
- Animal Models for Evaluating Immune Responses of Human Effector Cells In Vivo
- Targeted Immune Therapy
- CD40 Stimulation and Antitumor Effects
- Immunocytokines: A Novel Approach to Cancer Immune Therapy
- Immune Escape: Role of Indoleamine 2,3-Dioxygenase in Tumor Tolerance
- Adoptive Transfer of T-Bodies: Toward an Effective Cancer Immunotherapy
- Targeting Toll-Like Receptor for the Induction of Immune and Antitumor Responses
- Manipulating TNF Receptors to Enhance Tumor Immunity for the Treatment of Cancer.